NEWSROOM

Biotechnology

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

IRVINE, Calif., Feb. 11, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Oncocyte will host one-on-one meetings with interested investors. Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to...

read more
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse Multicenter Phase 2a Trial Advancing to Higher Treatment Dose with Recruitment Expected to Conclude the First Half of 2025 Lipella Leadership to Present Findings at BIO CEO & Investor Conference on Tuesday, February 11, 2025, at 2:30 p.m. EST PITTSBURGH, Feb. 11, 2025 - PRISM...

read more
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Oncocyte Prices $29.1 Million Equity Offering

Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial Launch Strategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization IRVINE, Calif., Feb. 10, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE...

read more
Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Northwestern Medicine is a global leader in clinical trial research, including spine CLARITY is a randomized study designed to demonstrate Nociscan’s ability to improve surgical outcomes while reducing costs for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 6, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),...

read more
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

PITTSBURGH, February 6, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for an Expanded Access Program (EAP) for LP-310, an oral rinse formulation designed to treat oral lichen planus (OLP). LP-310 is an innovative, localized therapy formulated to...

read more
Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

The Company has secured nearly $20 million in gross proceeds in 2025 ensuring complete funding for its pivotal CLARITY trial CLARITY is a prospective, randomized, multicenter study to validate Nociscan’s ability to improve surgical outcomes Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Broomfield, CO, February 4, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON,...

read more
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference

Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI)  NOCISCAN as New Gold Standard in Identifying a Source of Discogenic Pain BROOMFIELD, Colo., January 31, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain,...

read more
Argentum 47, Inc. Announces Acquisition of Marelius Biopharma Group, Divestiture of Argentum Data Solutions, and Leadership Transition

Argentum 47, Inc. Announces Acquisition of Marelius Biopharma Group, Divestiture of Argentum Data Solutions, and Leadership Transition

Las Vegas, NV, January 21, 2025 - PRISM MediaWire - Argentum 47, Inc. (OTC PINK: ARGQ) (“Argentum” or the “Company”) today announced a series of transformative developments, including the acquisition of Marelius Biopharma Group (MBG), the divestiture of Argentum Data Solutions, and a leadership transition aimed at strengthening the Company’s strategic focus and shareholder value. Acquisition of Marelius Biopharma Group Argentum has acquired Marelius Biopharma Group (MBG), a UK-based company...

read more
Digital Utilities Ventures, Inc. Announces Strategic Partnership with TradersQue LLC to Support Growth and Expansion Initiatives

Digital Utilities Ventures, Inc. Announces Strategic Partnership with TradersQue LLC to Support Growth and Expansion Initiatives

Mankato, MN, January 15th, 2025 - PRISM MediaWire - Digital Utilities Ventures (OTC: DUTV), a green solutions company focused on regenerative agriculture and clean water technologies, is pleased to announce a strategic partnership with TradersQue LLC (www.TradersQue.com). The collaboration aims to leverage TradersQue’s innovative business solutions to support DUTV’s ongoing growth and expansion efforts across the Agricultural and other new markets. This partnership will provide DUTV with...

read more
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

POMPANO BEACH, Fla., January 13, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced selected preliminary financial results for the fiscal fourth quarter and full year ended December 31, 2024. 2024 Preliminary Fourth Quarter and Year End Results: Fourth quarter net revenue is expected to...

read more
Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

Company to present at 3:00 p.m. PT on Tuesday, January 14, at the Hilton San Francisco Union Square New York, NY, January 8, 2025 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s, and Parkinson’s disease, announces that it will present at Biotech Showcase 2025, an event expected to include over 3,200 healthcare professionals with more than 1,200...

read more
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicine Will provide key regulatory and reimbursement support Will assist business development efforts and strategic partnerships Irvine, Calif., Jan. 8, 2025 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company’s Consulting Chief Medical Officer. In this part-time role, he will support a...

read more
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

Study of Vendaje® versus standard of care aims to show superior wound treatment, supporting market expansion POMPANO BEACH, Fla., January 8, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces the initiation of the BR-AM-DFU (BioREtain® Amniotic Membrane - Diabetic Foot Ulcers) clinical trial to evaluate Vendaje® versus...

read more
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Medicare coverage expanded following study showing that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA) MolDX confirms eligibility for billing under current Local Coverage Determination (LCD) and Z-Code Up to 20% of patients will have detectable DSA within the first five years post kidney transplant, representing greater than 10,000 patients per year in the US.1 From time of onset of dnDSA, 24%...

read more
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Technologies CEO to Present at Biotech Showcase 2025

Presentation to be webcast at 2:30 PM PT on Monday, January 13, 2025 POMPANO BEACH, Florida, January 2, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, the Company’s Chief Executive Officer, will present a corporate overview and update at the Biotech Showcase 2025 conference, which is...

read more
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

January 13-16, 2025, San Francisco, CA IRVINE, Calif., December 9, 2024 - PRISM MediaWire - Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. Morgan Week,” coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, from January 13 - 16, 2025. During this period, Oncocyte will host one-on-one meetings with interested investors....

read more
Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences’ Scientific Advisory Board

Klotho Neurosciences, Inc. continues to strengthen its advisory teams with recent new additions of Neuroscience and Big Pharma leaders to Scientific Advisory Board and Board of Directors New York, NY, December 9, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s and Parkinson’s disease is proud to announce the appointment of Dr. Merit Cudkowicz,...

read more
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study

IRVINE, Calif., Dec. 04, 2024 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number...

read more
Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

Former Merck USA President Joins Klotho Neurosciences’ Board of Directors

Highly Accomplished Pharmaceutical Leader, Riad El-Dada, Further Enhances Board Expertise NEW YORK, Dec. 03, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer’s, and Parkinson’s, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical...

read more
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus

Peer-reviewed article highlights potential treatment for OLP with focus on localized drug delivery PITTSBURGH, Dec. 03, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet needs, today announced the publication of a peer-reviewed paper in CUREUS. Titled “Rationale for the Use of Topical Calcineurin Inhibitors in the Management of Oral Lichen Planus and Mucosal...

read more
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms 

Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population  Study shows that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies  Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated rejection.  Study published in Nephrology Dialysis...

read more
Halberd Update on WatchDawg® PTSD Treatment

Halberd Update on WatchDawg® PTSD Treatment

Next Phase Pilot Study Jackson Center, PA, December 2, 2024 - PRISM MediaWire - Halberd Corporation (OTC PINK: HALB) previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation.  The results of that study can be found here.  Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software...

read more
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

Company continues to advance its placental-derived product portfolio with the first patent granted in the fenestrated wound care market POMPANO BEACH, Fla., Nov. 25, 2024 - PRISM MediaWire - BioStem Technologies, Inc.  (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for...

read more
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

PITTSBURGH, November 21, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, today announced the completion of dosing for the first cohort in its multi-center Phase 2a clinical trial of LP-310, a liposomal-tacrolimus oral rinse being developed for the treatment of Oral Lichen Planus (OLP). In this first cohort, eight...

read more
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

Additions of ProgenaMatrix®and revyve™ Antimicrobial Wound Gel part of planned expansion of BioStem’s commercial product portfolio POMPANO BEACH, Fla., November 20, 2024 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, today announced the signing of a Letter of Intent (LOI) to acquire commercial-stage products and development technologies from ProgenaCare Global...

read more
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Company advancing late-stage clinical programs with novel therapies that target underserved heart diseases NEW YORK, November 13, 2024 - PRISM MediaWire - PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market impact within the biotech sector. Cardiol’s focus on anti-inflammatory and...

read more
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phase FDA pre-submission process for approval of kitted clinical test is underway IRVINE, Calif., Nov. 12, 2024 - PRISM MediaWire - Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today published the following letter to shareholders in conjunction with its third...

read more
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million

Company reports third sequential quarter of record growth, contributing to a record total of $199.0 million in revenue for the first nine-months of 2024 Achieves third consecutive quarter of positive GAAP net income of $6.8 million or $0.42 per share. Generated Q3 2024 Adjusted EBITDA of $9.9 million Financial Results Conference Call and Webcast on Tuesday, November 12, 2024, at 4:30 pm ET POMPANO BEACH, FL, November 12, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (the...

read more
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

PITTSBURGH, November 12, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office (USPTO) on November 12, 2024. This patent, titled "Delivery of Agents Using Metastable Liposomes," covers...

read more
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Nov. 6, 2024 - PRISM MediaWire -  Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss...

read more

Contact Us

PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850